Key Takeaway: 4D Molecular Therapeutics has developed a gene therapy that significantly reduces the number of injections required for patients suffering from diabetic macular edema. This therapy is a variant of Regeneron's Eylea, aiming to enhance treatment efficacy and patient comfort. The innovation could lead to better adherence to treatment regimens.
Price reaction · baseline $10.7 (2025-12-03 close) · hit pre-market · 5 other FDMT headline(s) in the window, move may be shared
day 0 close · peak
+4.6%
Market Sentiment Analysis
POSITIVE FACTORS
4DMT's gene therapy reduces the need for frequent injections.
The therapy offers a new treatment option for diabetic macular edema.
Potentially improves patient compliance and quality of life.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+128%
120-day peak, hindsight
Typical move
11.2%
average across 9 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
4D-150 IVT
Phase 3 · Macular Neovascularization Secondary to Age-Related Macular Degeneration
Full Press Release Details
Lei Lei Wu
News Reporter
4D Molecular Therapeutics’ gene therapy version of Regeneron’s Eylea reduced the number of injections that patients with diabetic macular edema need over a year.
However …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.